Our Viaskin Technology is a broad platform
We believe that our broadly applicable technology platform, know-how and deep understanding of EPIT® positions us well to develop product candidates in areas of unmet medical need in immunotherapy.
We currently expect to selectively conduct product development programs outside of our core food allergy expertise in collaboration with companies or agencies that are experts in their field.
To date, we have signed several collaboration agreements to broaden the number of indications We are pursuing with our Viaskin® technology platform. These collaboration agreements are in the early proof-of-concept phase.